Search Results - "DeFilippis, E."

Refine Results
  1. 1

    The genetics of pyoderma gangrenosum and implications for treatment: a systematic review by DeFilippis, E.M., Feldman, S.R., Huang, W.W.

    Published in British journal of dermatology (1951) (01-06-2015)
    “…Summary Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by painful skin ulcerations for which treatment can be challenging. The…”
    Get full text
    Journal Article
  2. 2

    The Association Between Socioeconomic Status, Sex, Race / Ethnicity and In-Hospital Mortality Among Patients Hospitalized for Heart Failure by Averbuch, T., Mohamed, M.O., Islam, S., Defilippis, E.M., Breathett, K., Alkhouli, M.A., Michos, E.D., Martin, G.P., Kontopantelis, E., Mamas, M.A., Van Spall, H.G.C.

    Published in Journal of cardiac failure (01-05-2022)
    “…•Among 4.3 million HF hospitalizations (5.1% deaths), low socioeconomic status (SES), male sex, and White race / ethnicity were independently associated with…”
    Get full text
    Journal Article
  3. 3

    Sex Differences in Characteristics and Outcomes Following HeartMate 3 Left Ventricular Assist Device Implantation by DeFilippis, E., Haythe, J., Marshall, D., Lin, E., Axsom, K., Truby, L., Yuzefpolskaya, M., Colombo, P., Sayer, G., Takayama, H., Takeda, K., Naka, Y., Farr, M., Uriel, N., Topkara, V.K.

    “…In addition to goal-directed therapies, advanced therapies for heart failure including left ventricular assist devices (LVADs) remain underutilized in women…”
    Get full text
    Journal Article
  4. 4

    HeartMate II Risk Score (HMRS) and MELD-Xi Scores Do Not Predict Mortality in HeartMate 3 LVAD Patients by Marshall, D., Truby, L., DeFilippis, E., Malick, A., Butler, C., Masoumi, A., Haythe, J., Axsom, K., Lin, E., Yuzefpolskaya, M., Colombo, P., Sayer, G., Takayama, H., Takeda, K., Naka, Y., Farr, M., Uriel, N., Topkara, V.K.

    “…Heartmate II risk score (HMRS) and MELD-Xi score are validated mortality risk predictors in Heartmate II left ventricular assist device (LVAD) patients…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Sex Differences in Myocardial Flow Reserve by Positron Emission Tomography in Heart Transplant Recipients by DeFilippis, E.M., Clerkin, K.J., Griffin, J.M., Fried, J.A., Latif, F., Restaino, S.W., Colombo, P.C., Yuzefpolskaya, M., Topkara, V.K., Takeda, K., Uriel, N., Farr, M.A., Bokhari, S.

    “…Coronary allograft vasculopathy (CAV) following heart transplantation (HT) is a major cause of morbidity and mortality. Assessment of myocardial flow reserve…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    (175) Characteristics and Outcomes of Multiple Cardiac Re-Transplant Recipients by Batra, J., Rosenblum, H., DeFilippis, E., Donald, E., Clerkin, K., Topkara, V., Lee, S., Latif, F., Yuzefpolskaya, M., Colombo, P., Oh, K., Lotan, D., Raikhelkar, J., Sayer, G., Uriel, N.

    “…A subset of HT recipients are considered for cardiac re-transplantation for various forms of graft dysfunction. Outcomes of individuals who undergo ≥2…”
    Get full text
    Journal Article
  17. 17
  18. 18

    (361) New System, Familiar Problem: Increased Wait Time for High Priority Heart Transplant Candidates by Harris, E.S., Sewanan, L., Topkara, V., Fried, J., Raikhelkar, J., Colombo, P., Yuzefpolskaya, M., DeFilippis, E., Latif, F., Takeda, K., Hassanein, M., Singh, S., Sayer, G., Uriel, N., Clerkin, K.

    “…The 2018 OPTN heart allocation policy was modified with a stated goal of improving access to individuals with the greatest medical need through improved…”
    Get full text
    Journal Article
  19. 19
  20. 20